Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS APPLAUDS JAPANESE GOVERNMENT NEW REGULATION SUPPORTING DIAGNOSIS, SUCH AS FFR, BEFORE TREATMENT OF CORONARY STENOSIS

24 April 2018

Quebec City, Quebec, April 24, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) applauds Japan’s Ministry of Health, Labor and Welfare (“MHLW”) on its new regulation requiring the evaluation of any coronary stenosis prior to its treatment, specifically mentioning Fractional Flow Reserve (“FFR”) as a preferred assessment method. The MHLW recently revised medical…

Read more

OPSENS REPORTS Q2 2018 RESULTS – CONSOLIDATED PRODUCT SALES UP 44%

12 April 2018

Quebec City, Quebec, April 12, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter ended February 28, 2018. Highlights Consolidated product sales reached $5,352,000 compared with $3,710,000 for the same period last year, an increase of $1,642,000 or 44,3%; Fractional Flow Reserve (“FFR”) revenues reached $3,313,000…

Read more

OPSENS’ TECHNOLOGY GRANTED FDA APPROVAL IN ABIOMED’S IMPELLA CARDIAC PUMP®

3 April 2018

Quebec City, Quebec, April 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces that the integration of Opsens’ technology, within the Impella Cardiac Pump® (“Impella CP®“), marketed by its client Abiomed, Inc. (” Abiomed “), is approved by the US Food and Drug Administration (” FDA “). This news follows the US$6 million…

Read more